India mandates tighter drug quality norms, raising compliance pressure across pharma supply
Revised Schedule M quality norms are now mandatory, requiring non-compliant manufacturers to upgrade or exit. The policy push also spans domestic API production, biologics, Jan Aushadhi expansion, trade-margin controls and closer medical-device procurement scrutiny.
What happened
Department of Pharmaceuticals · India is enforcing revised WHO-GMP quality norms, requiring non-compliant drugmakers to upgrade or close. The government is also
Key facts
- Revised Schedule M mandatory from January 1
- Four or five companies manufacture GLP-1 drugs in India
- Essential medicine prices cannot rise by more than 10% annually
- Around 80% of medicines are outside price control
- 30-35% of drugs rely on Chinese APIs
- 60-65% of drugs have a fully domestic value chain
Why this matters
Target partnerships or acquisitions involving quality-compliant manufacturers, API capacity and affordable-medicine distribution platforms positioned to benefit from consolidation.
What to watch
- State and central inspection outcomes, warning letters, plant shutdowns and Schedule M compliance deadlines or extensions.
- Drug shortage notices, stock-out rates and price increases in essential medicines, injectables, anti-infectives and chronic therapies.
- Manufacturer capex announcements, merger activity, contract-manufacturing demand and exits among small and mid-sized generic producers.
- Jan Aushadhi store expansion, procurement tender awards and changes in availability of government-backed generic SKUs.
- New trade-margin caps, National Pharmaceutical Pricing Authority actions and enforcement against distributor or retailer markups.
- Domestic API incentive awards, biologics manufacturing approvals and medical-device procurement rules that redirect sourcing toward audited local suppliers.
- Audit exposure by molecule, manufacturer and therapy category, prioritizing antibiotics, injectables, chronic-care generics and high-volume Jan Aushadhi SKUs.
- Secure dual sourcing and longer-term supply agreements with Schedule M-compliant manufacturers; build selective safety stock for vulnerable essential medicines.
- Reprice procurement models to separate temporary shortage premiums from durable manufacturer cost inflation, while protecting price-sensitive generic baskets.
- Expand supplier quality-scorecard requirements for distributors, franchisees and private-label partners, including plant compliance status and recall history.
- Use compliant domestic API and formulation suppliers as a strategic sourcing narrative for institutional, hospital and government-tender business.
- Monitor trade-margin controls before raising consumer prices; shift mix toward services, diagnostics, wellness and higher-margin categories if prescription-drug margins tighten.